Principal Investigator
Noa Holtzman
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240096
Clinical Trial Summary
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Phase
Phase I/II
Funding Agency/Sponsor
Externally Peer-Reviewed
Disease
Transplant/cellular therapy
Contact Information
Phone Number
305-243-2647